Cell News and Research

RSS

UCLA finds link between high cholesterol and osteoporosis

A new UCLA study sheds light on the link between high cholesterol and osteoporosis and identifies a new way that the body's immune cells play a role in bone loss

25 Aug 2009

INSERM researchers engineer a chimeric protein that improves stem cell engraftment

Researchers at INSERM (France) have engineered a chimeric protein that increases cell survival, migration and proliferation to improve stem cell engraftment. The results, which appear in the September 2009 issue of Experimental Biology and Medicine, show that TAT-Tpr-Met, a cell permeable form of the hepatocyte growth factor receptor can increase the number of hepatic stem cells integrated into the liver of the mouse.

24 Aug 2009

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer.

24 Aug 2009

New research results reveal that two Parkinson genes can maintain the mitochondrial functions

Parkinson's disease is caused by the degeneration of neurons in the midbrain. The mechanisms leading to the loss of these neurons, however, are largely unknown. Recent research revealed that about ten per cent of cases are caused by defects in so-called Parkinson-associated genes. Furthermore, mitochondria, the cellular powerhouses, seem to play a major role. New results from researchers at the LMU Munich under the lead of associate professor Dr. Konstanze Winklhofer and Professor Christian Haass connect both phenomena, showing that two Parkinson genes maintain the function of mitochondria.

24 Aug 2009

CDEX's ID2 Meth Scanner to help combat the growing problem of methamphetamine use

CDEX Inc. announces completion of development-phase testing of a new generation Meth Scanner™ that embodies cell-phone technology and multi-filter applications. The new generation Scanner will have a cell-phone-interactive readout that increases functionality to provide more options for the law enforcement community in its battle against methamphetamine use. In addition, the technological advancements of multi-filter integration will provide greater sensitivity and a platform for multi-drug applications for the Scanner.

24 Aug 2009

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), a leading developer of adult stem cell technologies and therapeutics, announced today that the company has secured the funding required to complete pre-clinical trials underway for the treatment of ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease). The company expects to begin Phase I clinical studies in 2010.

24 Aug 2009

ARIAD's petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and its co-plaintiffs today announced that the U.S. Court of Appeals for the Federal Circuit (the “Federal Circuit”) has granted their petition for rehearing en banc and has vacated its April 2009 decision in the appeal that Eli Lilly and Co. filed in 2008. All twelve judges of the Federal Circuit will now rehear and reassess the merits of Lilly’s appeal.

24 Aug 2009

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced positive data from a Phase 2 clinical study evaluating RX-10045, a resolvin administered as a topical eye drop for the treatment of patients with chronic dry eye syndrome.

24 Aug 2009

MIT to honor Dr. Khine of Shrink Nanotechnologies as one of the top 35 global innovators

Shrink Nanotechnologies, Inc. (“Shrink”) (OTCBB: INKN), an innovative nanotechnology company that develops products, licenses its patent-pending technologies and acquires related assets in three core vertical markets: (i) solar energy production, (ii) medical diagnostics and sensors and (iii) biotechnology research and development tools, today announced that Dr. Michelle Khine, Ph.D., the scientific founder of Shrink’s nanofabrication platform, was named by MIT Technology Review as one of the top 35 global innovators under the age of 35.

24 Aug 2009

XSpray Microparticles launches GMP production facility in Sweden

Karolinska Development (publ), managing one of the largest portfolios of life science research companies in Europe, announced that XSpray Microparticles AB has launched a GMP production facility in Malmo, Sweden. In addition to offering particle development and characterization services, XSpray can now provide customers with high quality drug particles and powders for use in their clinical studies.

24 Aug 2009

Study reveals that treating Alzheimer's disease with DHA and EPA slows down its progression

Scientists have identified the inflammatory process as the common soil in a diverse range of chronic degenerative diseases. The news, recently reported in the LA Times article, discusses how foods like cherries may help rheumatoid arthritis or avoidance of gluten may fight off psoriasis.

24 Aug 2009

Cell Therapeutics completes sale of Series 2 Preferred Stock and warrants

Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced the closing of its previously announced sale of $30 million of shares of its Series 2 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to a single institutional investor. The investor has elected to convert all of its shares of Series 2 Preferred Stock and to receive the 18,853,103 shares of the Company's common stock issuable upon such conversion at the closing.

24 Aug 2009

Two key circuits for controlling the cell's ability identified by UCSF researchers

UCSF researchers have identified the two key circuits that control a cell's ability to adapt to changes in its environment, a finding that could have applications ranging from diabetes and autoimmune research to targeted drug development for complex diseases.

24 Aug 2009

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Sigma-Aldrich(R) (Nasdaq: SIAL) announced today that scientists at its new Sigma Advanced Genetic Engineering (SAGE(TM)) Labs in St. Louis will leverage its exclusive CompoZr(TM) Zinc Finger Nuclease (ZFN) gene editing technology (www.compozrzfn.com) to define, develop and offer a new generation of genetically-engineered rodent research models. Such models are commonly used to study disease states in humans and play a key role in the drug discovery process.

24 Aug 2009

Primary cilia can suppress or promote skin cancer

Tiny, solitary spikes that stick out of nearly every cell in the body play a central role in a type of skin cancer, new research has found. The discovery in mice shows that the microscopic structures known as primary cilia can either suppress or promote this skin cancer, depending on the mutation triggering the disease.

24 Aug 2009

Research reveals that diarrheal bacteria can cause colon cancers

Johns Hopkins scientists say they have figured out how bacteria that cause diarrhea may also be the culprit in some colon cancers. The investigators say that strains of the common Bacteroides fragilis (ETBF) dupe immune system cells into permitting runaway colon tissue inflammation, a precursor for malignant growth.

24 Aug 2009

Tiny filaments extending from cells may play a role in common malignant brain tumors

UCSF scientists have discovered that a tiny filament extending from cells, until recently regarded as a remnant of evolution, may play a role in the most common malignant brain tumor in children.

24 Aug 2009

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Low levels of vitamin D are known to nearly double the risk of cardiovascular disease in patients with diabetes, and researchers at Washington University School of Medicine in St. Louis now think they know why.

24 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

Dean Evans & Associates rolls out new versions of facility scheduling and resource management tools

Dean Evans & Associates today announced the official rollout of new versions of their facility scheduling and resource management products. Used at more than 3,600 customer sites in the U.S. and abroad, EMS (Event Management System) software provides powerful tools for helping organizations be more efficient at reserving rooms, resources and personnel for meetings and events, managing resource inventories and communicating details to staff, meeting organizers and attendees.

24 Aug 2009

Cell News and Research

UCLA finds link between high cholesterol and osteoporosis

INSERM researchers engineer a chimeric protein that improves stem cell engraftment

Bioniche Life Sciences update on Phase III clinical program for evaluating Urocidin

New research results reveal that two Parkinson genes can maintain the mitochondrial functions

CDEX's ID2 Meth Scanner to help combat the growing problem of methamphetamine use

Israeli government and a private investment fund Brainstorm Cell Therapeutics to complete pre-clinical studies in ALS

ARIAD's petition for rehearing the Lilly NF-Kb patent lawsuit is granted by the Federal Circuit

Phase 2 clinical study of Resolvin RX-10045 for dry eye syndrome provides positive data

MIT to honor Dr. Khine of Shrink Nanotechnologies as one of the top 35 global innovators

XSpray Microparticles launches GMP production facility in Sweden

Study reveals that treating Alzheimer's disease with DHA and EPA slows down its progression

Cell Therapeutics completes sale of Series 2 Preferred Stock and warrants

Two key circuits for controlling the cell's ability identified by UCSF researchers

Sigma-Aldrich scientists to leverage proprietary gene editing technology to develop genetically-engineered rodent research models

Primary cilia can suppress or promote skin cancer

Research reveals that diarrheal bacteria can cause colon cancers

Tiny filaments extending from cells may play a role in common malignant brain tumors

Diabetics can reduce the risk of cardiovascular disease by increasing vitamin D levels

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Dean Evans & Associates rolls out new versions of facility scheduling and resource management tools

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News